Omalizumab

RAPT Therapeutics and Jemincare enter an exclusive license agreement for RPT904, a novel anti-IgE monoclonal antibody, with RAPT gaining worldwide rights excluding China. Jemincare receives $35M upfront, up to $672.5M in milestones, and royalties. RAPT plans a Phase 2b trial in food allergy; Jemincare conducts Phase 2 trials in asthma and CSU in China.

RAPT Therapeutics and Jemincare announced an exclusive license agreement for RPT904, a novel anti-IgE monoclonal antibody, with RAPT gaining worldwide rights excluding China. Jemincare receives $35M upfront, up to $672.5M in milestones, and royalties. RAPT plans a Phase 2b trial in food allergy, while Jemincare conducts Phase 2 trials in asthma and CSU in China.

Peanut allergy treatments are advancing, with options like oral immunotherapy, biologics, and epicutaneous immunotherapy offering hope for better management. These methods aim to reduce severe reactions by gradually increasing tolerance to peanuts. While no cure exists, these treatments can significantly improve quality of life for those affected.

Health Canada approved Celltrion's Omlyclo, the first omalizumab biosimilar in Canada, for treating chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps. Omlyclo demonstrated bioequivalence to Xolair in a phase 3 study, and is under FDA review. Celltrion also received positive CHMP opinions for three other biosimilars in Europe.

Celltrion Inc. receives Health Canada approval for Omlyclo, a biosimilar of Xolair, enabling sales in Canada for allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic idiopathic urticaria.

DBV Technologies progresses with Viaskin patch for peanut and milk allergies, aiming for FDA approval. Studies show promising results, with 81% of toddlers tolerating peanuts after 2 years. The patch, part of epicutaneous immunotherapy, may offer sustained unresponsiveness. DBV plans to expand treatment to cashew and potentially other allergens.

The microbial fermentation technology market was valued at USD 31.97 Billion in 2023 and is projected to reach USD 53.25 Billion by 2032, growing at a CAGR of 5.91%. This growth is driven by advancements in biotechnology, demand for sustainable production, and investments in alternative protein companies. Key segments include antibiotics, monoclonal antibodies, and CMOs & CDMOs, with Asia Pacific leading the market and North America poised for fast growth.

Anabelle Terry, with a lifelong nut allergy, now eats nuts due to a study using Omalizumab (Xolair), which binds to allergy cells, reducing reactions. The study showed kids previously reacting to less than a third of a peanut could tolerate more than two whole peanuts. The drug gained FDA approval in February for treating severe allergies, usable from age one.